| Literature DB >> 7623049 |
G R Pettit1, G R Pettit1, G Groszek, R A Backhaus, D L Doubek, R J Barr, A W Meerow.
Abstract
Seven species (and one cultivated variety) of Hymenocallis (Amaryllidaceae) and the related Pancratium maritima, representing a broad geographical selection, were investigated as sources of pancratistatin [1] now undergoing preclinical development as an anticancer agent. Pancratistatin [1] was found to be a constituent of H. speciosa (Singapore), H. variegated (Singapore), H. pedalis (Seychelles), H. expansa (Bermuda), H. sonoranensis (Mexico), and P. maritimum (Israel). Only two species of Hymenocallis failed to yield one or more of the related cell-growth inhibitory isocarbostyrils such as narciclasine [3a], 7-deoxynarciclasine [3b], and 7-deoxy-trans-dihydronarciclasine [2].Entities:
Mesh:
Substances:
Year: 1995 PMID: 7623049 DOI: 10.1021/np50119a017
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050